Johnson & Johnson ensures that its Janssen single-dose vaccine against Covid-19 is effective against the Delta variant, initially spotted in India and particularly contagious, with an immune response that can last at least eight months.
Read also: Contagiousness, immunity, dangerousness: should we be afraid of the Delta variant?
According to a study carried out by the American pharmaceutical group on a small number of eight people vaccinated with its vaccine, the antibodies and the cells of their immune system neutralized the Delta variant.
A second study of 20 vaccinated patients from Beth Israel Medical Center in Boston yielded the same results.
The data from these studies were sent to the
BioRxiv
“
pre-publication
” platform, where scientists can submit their work before possible publication in a scientific journal.
"A strong neutralizing antibody response"
"
We believe that our vaccine offers lasting protection against Covid-19 and allows neutralization of the Delta variant
," said Paul Stoffels, scientific director of Johnson & Johnson quoted in a statement released Thursday evening.
Data "
over the eight months studied so far
" show that the single-dose vaccine developed by the laboratory "
produces a strong neutralizing antibody response that does not decrease, we even observe an improvement over time,
" said Mathai Mammen. , Head of Research and Development at Johnson & Johnson.
New wave risk
WHO warned Thursday of a risk of a new wave of the pandemic carried by the Delta variant in Europe, when it launches its health pass in the hope of reviving tourism, while the number of cases increases at "
an alarming rate
" in Africa. Asia is not spared: Bangladesh has been subject to containment since Thursday and restrictions are announced for Saturday in Indonesia, in the face of a sharp rise in contamination.